Physician profile
David Porter
NPI 1386139285
$8,814.97
in general payments reported to CMS, 2019-2025
24 companies · $3,708 in 2025
The $3,708 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920 · 2022: $1,043 · 2023: $597 · 2024: $2,548 · 2025: $3,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,849 · Food and Beverage: $2,507 · Travel and Lodging: $1,385 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,849.00 |
| Food and Beverage | $2,507.15 |
| Travel and Lodging | $1,384.65 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,550.18 | 2024-2025 | Rejoyn |
| Abbvie INC. | $1,136.85 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $716.71 | 2021-2025 | Caplyta |
| Alkermes, INC. | $376.20 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $306.44 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $291.77 | 2021-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $271.07 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $266.57 | 2021-2025 | Spravato, Invega |
| Sunovion Pharmaceuticals INC. | $160.38 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $126.80 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $102.47 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $102.19 | 2021-2022 | |
| Indivior INC. | $88.35 | 2021-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $53.55 | 2022-2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $50.04 | 2024-2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $45.67 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $36.80 | 2021 | |
| Edwards Lifesciences Corporation | $30.84 | 2025 | |
| Exact Sciences Corporation | $24.93 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $17.70 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $16.91 | 2023 | Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2024 | Trulance, Xifaxan |
| Novo Nordisk INC | $14.67 | 2025 | Rybelsus, Ozempic |
| Almatica Pharma LLC | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.